CLX Clorox
Wounded staples franchise; value hinges on margins returning to ~16.5%, not on growth.
The story
Clorox is a mature household-staples franchise (bleach, Glad, Kingsford, Hidden Valley, Brita) with strong shelf positions in the US, but the last five years have been rough. The COVID demand spike faded, cost inflation squeezed margins, a 2023 cyberattack disrupted operations, the ERP cutover caused problems, and the company sold off Argentina and VMS. Revenue is shrinking while it pushes margins back toward its historical mid-to-high teens. It is a no-growth, cash-generating business with meaningful leverage and steady pressure from private labels.
After the divestitures and ERP disruption, revenue should stabilize with low-single-digit growth that converges to inflation-like 2%. Pricing and cost savings rebuild margins to about 16.5%, below the pre-COVID 18% peak because retailer and private-label pressure persists. Reinvestment needs are low since this is a mature brand portfolio. Beta stays at the staples anchor, with a small failure probability reflecting about 3.5x net debt to EBITDA.
Value drivers
| Revenue growth (Y1) | 1.0% |
| Terminal growth | 2.0% |
| Forecast horizon | 6y |
| Target operating margin | 16.5% |
| Years to target margin | 4 |
| Sales-to-capital | 1.50 |
| Beta | 0.70 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 7.8% |
| Terminal WACC | 8.7% |
Valuation bridge
| PV of explicit FCFF | 3.58B |
| PV of terminal value | 7.59B |
| Equity value | 5.97B |
| ÷ shares → per share | $49.35 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 6.79B | 1.0% | 14.4% | 742.80M | 44.80M | 698.00M | 647.44M |
| 2 | 6.87B | 1.2% | 15.1% | 788.18M | 54.30M | 733.88M | 631.42M |
| 3 | 6.96B | 1.4% | 15.8% | 836.18M | 64.11M | 772.07M | 616.17M |
| 4 | 7.08B | 1.6% | 16.5% | 887.12M | 74.29M | 812.83M | 601.71M |
| 5 | 7.20B | 1.8% | 16.5% | 903.09M | 84.91M | 818.18M | 561.80M |
| 6 | 7.35B | 2.0% | 16.5% | 921.15M | 96.05M | 825.11M | 525.52M |
Key risks
- Private-label share gains and promotional intensity cap pricing power and margin recovery
- Volume declines persist beyond ERP and divestiture effects, signaling structural brand erosion
- Leverage (net debt ~4.9B) limits flexibility; dividend commitments could strain cash flow if margins stall
Catalysts
- Lapping of ERP transition and divestiture comps showing organic volume stabilization
- Gross margin rebuild from cost savings program and commodity relief lifting EBIT margin back above 15%